Integrating transformers and many-objective optimization for drug design

被引:3
作者
Aksamit, Nicholas [1 ]
Hou, Jinqiang [3 ,4 ]
Li, Yifeng [1 ,2 ]
Ombuki-Berman, Beatrice [1 ]
机构
[1] Brock Univ, Dept Comp Sci, 1812 Sir Isaac Brock Way, St Catharines, ON L2S 3A1, Canada
[2] Brock Univ, Dept Biol Sci, 1812 Sir Isaac Brock Way, St Catharines, ON L2S 3A1, Canada
[3] Lakehead Univ, Dept Chem, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada
[4] Thunder Bay Reg Hlth Res Inst, 980 Oliver Rd, Thunder Bay, ON P7B 6V4, Canada
关键词
Drug design; Molecular generation; Transformers; Many-objective optimization; Evolutionary algorithm; Particle swarm optimization; ADMET; LPA1; LYSOPHOSPHATIDIC ACID; ALGORITHM; DISCOVERY;
D O I
10.1186/s12859-024-05822-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background Drug design is a challenging and important task that requires the generation of novel and effective molecules that can bind to specific protein targets. Artificial intelligence algorithms have recently showed promising potential to expedite the drug design process. However, existing methods adopt multi-objective approaches which limits the number of objectives.Results In this paper, we expand this thread of research from the many-objective perspective, by proposing a novel framework that integrates a latent Transformer-based model for molecular generation, with a drug design system that incorporates absorption, distribution, metabolism, excretion, and toxicity prediction, molecular docking, and many-objective metaheuristics. We compared the performance of two latent Transformer models (ReLSO and FragNet) on a molecular generation task and show that ReLSO outperforms FragNet in terms of reconstruction and latent space organization. We then explored six different many-objective metaheuristics based on evolutionary algorithms and particle swarm optimization on a drug design task involving potential drug candidates to human lysophosphatidic acid receptor 1, a cancer-related protein target.Conclusion We show that multi-objective evolutionary algorithm based on dominance and decomposition performs the best in terms of finding molecules that satisfy many objectives, such as high binding affinity and low toxicity, and high drug-likeness. Our framework demonstrates the potential of combining Transformers and many-objective computational intelligence for drug design.
引用
收藏
页数:25
相关论文
共 68 条
[1]   Adversarial deep evolutionary learning for drug design [J].
Abouchekeir, Sheriff ;
Vu, Andrew ;
Mukaidaisi, Muhetaer ;
Grantham, Karl ;
Tchagang, Alain ;
Li, Yifeng .
BIOSYSTEMS, 2022, 222
[2]   Structure of the active Gi-coupled human lysophosphatidic acid receptor 1 complexed with a potent agonist [J].
Akasaka, Hiroaki ;
Tanaka, Tatsuki ;
Sano, Fumiya K. ;
Matsuzaki, Yuma ;
Shihoya, Wataru ;
Nureki, Osamu .
NATURE COMMUNICATIONS, 2022, 13 (01)
[3]  
Angelo JS, 2023, chemRxiv, DOI [10.26434/chemrxiv-2023-q0zdf, 10.26434/chemrxiv-2023-q0zdf, DOI 10.26434/CHEMRXIV-2023-Q0ZDF]
[4]   Multi-and many-objective optimization: present and future in de novo drug design [J].
Angelo, Jaqueline S. ;
Guedes, Isabella A. ;
Barbosa, Helio J. C. ;
Dardenne, Laurent E. .
FRONTIERS IN CHEMISTRY, 2023, 11
[5]   The influence of lipophilicity in drug discovery and design [J].
Arnott, John A. ;
Planey, Sonia Lobo .
EXPERT OPINION ON DRUG DISCOVERY, 2012, 7 (10) :863-875
[6]   HypE: An Algorithm for Fast Hypervolume-Based Many-Objective Optimization [J].
Bader, Johannes ;
Zitzler, Eckart .
EVOLUTIONARY COMPUTATION, 2011, 19 (01) :45-76
[7]   Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special? [J].
Balijepalli, Pravita ;
Sitton, Ciera C. ;
Meier, Kathryn E. .
CELLS, 2021, 10 (08)
[8]  
Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/nchem.1243, 10.1038/NCHEM.1243]
[9]  
Bohacek RS, 1996, MED RES REV, V16, P3, DOI 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.3.CO
[10]  
2-D